Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

On: November 4, 2020

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex. GW’s total revenue for the third quarter reached $137.1 million, about 16% more than the previous quarter’s $121.3 million. Epidiolex sales in the United States accounted for 87% of the company’s overall […]

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Previous Post: Los Angeles hit with another marijuana social equity lawsuit

Next Post: 2020 election results signal growing public approval of cannabis

Comments are closed, but trackbacks and pingbacks are open.